Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Have Clinical Trials Shown That Cannabis Reduces AHI in Sleep Apnoea? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Understanding whether cannabis can improve obstructive sleep apnoea (OSA) outcomes requires a close look at cannabis clinical trials. Researchers have explored the effects of cannabinoids on apnoea-hypopnea index (AHI), aiming to assess their potential for reducing the frequency of sleep interruptions. 

Am I eligible for medical cannabis for pain relief?

Insights From Clinical Research 

Current cannabis clinical trials suggest that cannabinoids may influence respiratory stability during sleep, but results are mixed and vary based on dosage and cannabinoid type. 

Evidence of AHI Reduction 

Some studies report AHI reduction with cannabis, particularly using THC-based treatments like dronabinol. These trials show modest decreases in apnoea events, although effects are not universal. 

Study Limitations 

Cannabis clinical trials often involve small sample sizes, short durations, and limited follow-up, making it difficult to generalise outcomes across all OSA patients. 

Mechanistic Understanding 

The research provides clinical evidence on OSA that cannabinoids may act on respiratory control pathways, potentially stabilising breathing and improving oxygenation during sleep. 

Safety and Tolerability 

Clinical trials also monitor side effects, highlighting the importance of balancing therapeutic benefits with risks such as daytime sleepiness or cardiovascular changes. 

While cannabis clinical trials provide promising insights into AHI reduction with cannabis, further large-scale studies are required. Current clinical evidence on OSA supports cautious optimism but underscores the need for standardised dosing and long-term evaluation. 

If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories